IDWeek 2026: despite missing primary endpoint, LB6V shows promise in Lyme disease
The commercial opportunity for a prophylactic Lyme disease vaccine in the US and Europe is substantial. LB6V is well placed to capitalise on this gap in the market.
The commercial opportunity for a prophylactic Lyme disease vaccine in the US and Europe is substantial. LB6V is well placed to capitalise on this gap in the market.